Regular Article CLINICAL TRIALS AND OBSERVATIONS Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
نویسندگان
چکیده
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study Samantha M. Jaglowski, Jeffrey A. Jones, Veena Nagar, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Jennifer A. Woyach, Kristie A. Blum, Michael R. Grever, Kelly Smucker, Amy S. Ruppert, Nyla A. Heerema, Gerard Lozanski, Mona Stefanos, Brian Munneke, Jamie-Sue West, Jutta K. Neuenburg, Danelle F. James, Nathan Hall, Amy J. Johnson, and John C. Byrd
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Bruton tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor signaling pathway and is a novel therapeutic target in CLL. Ibrutinib (previously known as PCI-32765) is an irreversible BTK inhibitor that binds to cysteine 481 within the adenosine triphosphate binding site of the kinase domain. Ibrutinib given at a daily dose of 420 mg received an accelerated approval by the US Food and...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia John C. Byrd, John M. Pagel, Farrukh T. Awan, Andres Forero, Ian W. Flinn, Delva P. Deauna-Limayo, Stephen E. Spurgeon, Leslie A. Andritsos, Ajay K. Gopal, John P. Leonard, Amy J. Eisenfeld, Jeannette E. Bannink, Scott C. Stromatt, and Ri...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) play an important role in the biology of chronic lymphocytic leukemia (CLL) cells. Thalidomide is a first-generation immunomodulating agent that down-regulates TNFand VEGF. We initiated a phase 1/2 clinical trial to determine the safety and efficacy of combining thalidomide with fludarabine in patients with treatmentnaı̈ve...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest. Patients with relapsed or refractory leukemias or myelodysplastic syndromes...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FL...
متن کامل